Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2016, Article ID 2576496, 3 pages
http://dx.doi.org/10.1155/2016/2576496
Case Report

Hemorrhagic Pericardial Effusion with Tamponade: A Rare Adverse Effect of Infliximab—Case Report and Literature Review

1University of Michigan Medical School, Ann Arbor, MI, USA
2Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA

Received 14 July 2016; Accepted 28 September 2016

Academic Editor: Shigeko Inokuma

Copyright © 2016 Henry D. Lather and J. Michelle Kahlenberg. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Harney, F. D. O'Shea, and O. FitzGerald, “Peptostreptococcal pericarditis complicating anti-tumour necrosis factor α treatment in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 61, no. 7, pp. 653–654, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. D. D. Sweet, G. Isac, B. Morrison, J. Fenwick, and V. Dhingra, “Purulent pericarditis in a patient with rheumatoid arthritis treated with etanercept and methotrexate,” Canadian Journal of Emergency Medicine, vol. 9, no. 1, pp. 40–42, 2007. View at Google Scholar · View at Scopus
  3. N. L. Ambrose and P. G. O'Connell, “Anti-TNF α therapy does not always protect rheumatoid arthritis patients against developing pericarditis,” Clinical and Experimental Rheumatology, vol. 25, no. 4, p. 660, 2007. View at Google Scholar
  4. S. J. L. Hall and P. Hickling, “Failure of etanercept to control extra-articular manifestations of rheumatoid arthritis,” Journal of Clinical Rheumatology, vol. 13, no. 1, p. 54, 2007. View at Publisher · View at Google Scholar
  5. M. C. Soh, H. H. Hart, and M. Corkill, “Pericardial effusions with tamponade and visceral constriction in patients with rheumatoid arthritis on tumour necrosis factor (TNF)-inhibitor therapy,” International Journal of Rheumatic Diseases, vol. 12, no. 1, pp. 74–77, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. M. H. Edwards and A. M. Leak, “Pericardial effusions on anti-TNF therapy for rheumatoid arthritis—a drug side effect or uncontrolled systemic disease?” Rheumatology, vol. 48, no. 3, pp. 316–317, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. G. K. Taylor, L. Elliott, M. D. Sosin, and S. S. Soo, “Complication of etanercept treatment for rheumatoid arthritis-purulent pericarditis caused by a commensal organism,” BMJ Case Reports, vol. 8, article 2012, 2012. View at Publisher · View at Google Scholar
  8. S. Hanauer, “Review article: safety of infliximab in clinical trials,” Alimentary Pharmacology and Therapeutics, vol. 13, no. s4, pp. 16–22, 1999. View at Publisher · View at Google Scholar
  9. J. P. Burke, B. Kelleher, S. Ramadan, M. Quinlan, D. Sugrue, and M. A. O'Donovan, “Pericarditis as a complication of infliximab therapy in Crohn's disease,” Inflammatory Bowel Diseases, vol. 14, no. 3, pp. 428–429, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. D. T. Harnett, H. B. Chandra-Sekhar, and S. F. Hamilton, “Drug-induced lupus erythematosus presenting with cardiac tamponade: a case report and literature review,” Canadian Journal of Cardiology, vol. 30, no. 2, pp. 247.e11–247.e12, 2014. View at Publisher · View at Google Scholar
  11. H. Ozkan, A. S. Cetinkaya, T. Yildiz, and T. Bozat, “A rare side effect due to TNF-alpha blocking agent: acute pleuropericarditis with adalimumab,” Case Reports in Rheumatology, vol. 2013, Article ID 985914, 2 pages, 2013. View at Publisher · View at Google Scholar
  12. J. Devasahayam, U. Pillai, and A. Lacasse, “A rare case of pericarditis, complication of infliximab treatment for Crohn's disease,” Journal of Crohn's and Colitis, vol. 6, no. 6, pp. 730–731, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. J.-Y. Wu, S.-H. Lee, C.-J. Shen et al., “Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis,” Arthritis and Rheumatism, vol. 64, no. 9, pp. 3034–3042, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Meisner, “Update on procalcitonin measurements,” Annals of Laboratory Medicine, vol. 34, no. 4, pp. 263–273, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Robier, M. Neubauer, and G. Reicht, “Marked elevation of procalcitonin in a patient with a drug related infusion reaction to rituximab,” Clinical Chemistry and Laboratory Medicine, vol. 54, no. 3, pp. e101–e103, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. J. Kim, S. W. Kang, J. H. Lee, and J. H. Cho, “Marked elevation of procalcitonin level can lead to a misdiagnosis of anaphylactic shock as septic shock,” International Journal of Infectious Diseases, vol. 37, pp. 93–94, 2015. View at Publisher · View at Google Scholar · View at Scopus